Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.
Fiche publication
Date publication
mai 2017
Journal
Blood cancer journal
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CHRETIEN Marie-Lorraine
Tous les auteurs :
Duchmann M, Braun T, Micol JB, Platzbecker U, Park S, Pilorge S, Beyne-Rauzy O, Vey N, Sébert M, Gruson B, Dumas PY, Guieze R, Chretien ML, Laribi K, Chait Y, Legros L, Sahnes L, Hirsch P, Salanoubat C, Solary E, Fenaux P, Itzykson R
Lien Pubmed
Mots clés
Adult, Aged, Antimetabolites, Antineoplastic, therapeutic use, Azacitidine, analogs & derivatives, DNA Methylation, drug effects, Decitabine, Female, Humans, Leukemia, Myelomonocytic, Chronic, drug therapy, Male, Middle Aged, Myelodysplastic Syndromes, drug therapy, Myelodysplastic-Myeloproliferative Diseases, drug therapy, Survival Analysis, Treatment Outcome
Référence
Blood Cancer J. 2017 05 12;7(5):e562